SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine
design, development and delivery, announced today that Dr. J. Joseph
Kim, Inovio’s CEO, presented keynote remarks at MIT’s Emerging
Technologies Conference hosted by the Massachusetts Institute of
Technology. (Read Dr. Kim’s speech.)
“The Promise of DNA Vaccines: A New Approach to
Vaccine Design, Drug Delivery and Disease Prevention”
The conference, which took place this week in Boston, annually attracts
top decision makers from companies in global business sectors ranging
from technology and engineering to investment and management consulting.
Dr. Kim’s speech, titled “The Promise of DNA Vaccines: A New Approach to
Vaccine Design, Drug Delivery and Disease Prevention,” focused on the
advantages of DNA vaccines versus traditional therapies, highlighting
their promise of enhanced speed of development, ease of manufacture, and
broader immune responses, as well as the “designer” nature of Inovio’s
novel vaccine approach. He discussed how Inovio’s DNA vaccine delivery
technology is showing the potential to overcome barriers that slowed the
development of DNA vaccines in the past. Inovio's universal vaccines
have shown preclinical results indicating their ability to protect
against new, unmatched strains of infectious diseases including the
currently circulating “swine” flu. Inovio is also developing vaccines
against HIV, HPV and cancer, with several studies currently in clinical
trials.
About Inovio Biomedical Corporation
Inovio Biomedical is engaged in the design, development, and delivery of
a new generation of vaccines, called DNA vaccines, focused on cancers
and infectious diseases. The company’s SynCon™ technology enables the
design of DNA-based vaccines capable of providing cross-protection
against new, unmatched strains of pathogens such as influenza. Inovio’s
proprietary electroporation-based DNA vaccine delivery technology has
been shown by initial human data to safely and significantly increase
gene expression and immune responses. Inovio’s clinical programs include
HPV/cervical cancer (therapeutic) and HIV vaccines. An IND has been
filed for an avian influenza vaccine. Inovio is developing its universal
and avian influenza vaccines in collaboration with scientists from the
University of Pennsylvania and the National Microbiology Laboratory of
the Public Health Agency of Canada. Other partners and collaborators
include Merck, Tripep, University of Southampton, National Cancer
Institute and HIV Vaccines Trial Network. More information is available
at www.inovio.com.
This press release contains certain forward-looking statements
relating to our plans to develop electroporation-based drug and gene
delivery technologies and DNA vaccines. Actual events or results may
differ from the expectations set forth herein as a result of a number of
factors, including uncertainties inherent in pre-clinical studies,
clinical trials and product development programs (including, but not
limited to, the fact that pre-clinical and clinical results referenced
in this release may not be indicative of results achievable in other
trials or for other indications, that results from one study may not
necessarily be reflected or supported by the results of other similar
studies and that results from an animal study may not be indicative of
results achievable in human studies), the availability of funding to
support continuing research and studies in an effort to prove safety and
efficacy of electroporation technology as a delivery mechanism or
develop viable DNA vaccines, the availability or potential availability
of alternative therapies or treatments for the conditions targeted by
the company or its collaborators, including alternatives that may be
more efficacious or cost-effective than any therapy or treatment that
the company and its collaborators hope to develop, evaluation of
potential opportunities, issues involving patents and whether they or
licenses to them will provide the company with meaningful protection
from others using the covered technologies, whether such proprietary
rights are enforceable or defensible or infringe or allegedly infringe
on rights of others or can withstand claims of invalidity and whether
the company can finance or devote other significant resources that may
be necessary to prosecute, protect or defend them, the level of
corporate expenditures, assessments of the company’s combined technology
by potential corporate or other partners or collaborators, capital
market conditions, our ability to successfully integrate Inovio and VGX
Pharmaceuticals, the impact of government healthcare proposals and other
factors set forth in our Annual Report on Form 10-K for the year ended
December 31, 2008, our Form 10-Q for the six months ended June 30, 2009,
and other regulatory filings from time to time. There can be no
assurance that any product in Inovio’s pipeline will be successfully
developed or manufactured, that final results of clinical studies will
be supportive of regulatory approvals required to market licensed
products, or that any of the forward-looking information provided herein
will be proven accurate.
Contacts
Investors:
Inovio Biomedical
Bernie Hertel, 858-410-3101
or
Media:
Richardson
& Associates
Jeff Richardson, 805-491-8313